In this issue:
- RA comorbidity clusters identify phenotype with favourable prognosis
- SGLT-2 inhibitors and nephritis in SLE
- Biological use influences impact of inflammation on CV event risk in RA
- Temporal artery ultrasonography when clinical suspicion of GCA is high
- Cost-effectiveness of biosimilars vs. leflunomide in RA
- Concomitant septic and crystal arthropathy
- First-line biological DMARDs in RA + CKD
- Approaches to acute AAV in Australasia
- Anti-TNF ± NSAID in radiographic axial SpA
- Corticoid-sparing methotrexate and leflunomide for polymyalgia rheumatica
Please login below to download this issue (PDF)